Next Article in Journal
Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/β-Catenin Pathway
Previous Article in Journal
Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(1), 5;

NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells

4,* and 1,2,*
Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, China
Beijing International Cooperation Base for Science and Technology on China–UK Cancer Research, Beijing 100069, China
Experiment Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
Core Facilities Center, Capital Medical University, Beijing 100069, China
Authors to whom correspondence should be addressed.
Academic Editor: William Chi-shing Cho
Received: 19 November 2016 / Revised: 9 December 2016 / Accepted: 13 December 2016 / Published: 12 January 2017
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Full-Text   |   PDF [3619 KB, uploaded 12 January 2017]   |  


Cervical cancer is one of the most common female malignancies, and cisplatin-based chemotherapy is routinely utilized in locally advanced cervical cancer patients. However, resistance has been the major limitation. In this study, we found that Na+/H+ Exchanger Regulatory Factor 1 (NHERF1) was downregulated in cisplatin-resistant cells. Analysis based on a cervical cancer dataset from The Cancer Genome Atlas (TCGA) showed association of NHERF1 expression with disease-free survival of patients received cisplatin treatment. NHERF1 overexpression inhibited proliferation and enhanced apoptosis in cisplatin-resistant HeLa cells, whereas NHERF1 knockdown had inverse effects. While parental HeLa cells were more resistant to cisplatin after NHERF1 knockdown, NHERF1 overexpression in CaSki cells promoted cisplatin sensitivity. Overexpression and knockdown studies also showed that NHERF1 significantly inhibited AKT and extracellular signal–regulated kinase (ERK) signaling pathways in cisplatin-resistant cells. Taken together, our results provide the first evidence that NHERF1 can sensitize cisplatin-refractory cervical cancer cells. This study may help to increase understanding of the molecular mechanisms underlying cisplatin resistance in tumors. View Full-Text
Keywords: cervical cancer; NHERF1; cisplatin resistance cervical cancer; NHERF1; cisplatin resistance

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Tao, T.; Yang, X.; Qin, Q.; Shi, W.; Wang, Q.; Yang, Y.; He, J. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells. Int. J. Mol. Sci. 2017, 18, 5.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top